Application of compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs

Abstract

The invention provides an application of a compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs. The application is characterized in that the tyrosine kinase inhibitor is selected from one of imatinib, gefitinib, erlotinib hydrochloride tablets, sorafenib, dasatinib tablets and tasigna or pharmaceutically acceptable salts or solvates or pharmaceutically acceptable salt solvents thereof; the tumor is selected from one of gastric cancer, liver cancer, lung cancer, kidney cancer, cervical cancer, pancreatic cancer, breast cancer, esophagus cancer, nasopharynxcancer and ovarian cancer; the mole ratio of resveratrol to tyrosine kinase inhibitor is (1-100):1.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the use of a composition containing a tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs. Background technique [0002] Tumors are a great threat to human health, and anti-tumor drug research is a very challenging and significant field in today's life sciences. In recent years, with the in-depth study of tumor pathogenic mechanisms, the basic process of signal transduction pathway changes in tumor cells is being gradually elucidated. Using key kinases in some cell signal transduction pathways as drug screening targets to discover new targeted drugs with high efficiency, low toxicity and strong specificity has become one of the effective ways for anticancer drug research today. At present, among all pharmacological targets, it is estimated that more than 1 / 4 of the targets are protein kinases, and it is as high as 75% in the field of anti-tumor, a...

AI Technical Summary

Problems solved by technology

Damiano S et al. (J Cell Biochem. 2018 Jun; 119(6):4845-4854. Reference 5) reported that antioxidants including resveratrol can significantly reduce the induction of dasatinib or nilotinib The level of MDA in K562 cells was significantly increased, and the ROS level in K562 cells induced by dasatinib or nilotinib was significantly increased, but the literature did not disclose whether the combination of resveratrol and dasatinib or nilotinib has synergy antitumor activity

Images